In recent years, with improvements in treatments for heart failure (HF), the survival period of
patients has been extended. However, the emergence of some patients with repeated …

Abstract Heart failure (HF) affects 6.2 million Americans and is increasing annually in its
frequency. Treatment of HF has been at the forefront of medical advancements due to the …

Introduction The significant morbidity and mortality in patients with heart failure (HF), notably
in the most advanced forms of the disease, justify the need for novel therapeutic options. In …

Introduction Despite significant therapeutic advancements in heart failure with reduced
ejection fraction (HFrEF), the residual risk of all-cause mortality and hospitalizations remains …

Despite recent advances in heart failure (HF) therapy, the risk of cardiovascular (CV)
mortality, morbidity, and HF hospitalization (HFH) are major challenges in HF treatment. We …

Heart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately
contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse …

Heart failure with reduced ejection fraction is a chronic and progressive syndrome that
continues to be a substantial financial burden for health systems in Western countries …

Vericiguat (Verquvo®) is the first oral soluble guanylate cyclase (sGC) stimulator to be
approved for the treatment of adults with symptomatic, chronic heart failure with reduced …

Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in
treating heart failure (HF). However, most studies have only confirmed the significant impact …

Objective To review the efficacy and safety of vericiguat indicated to reduce the risk of
cardiovascular death and heart failure (HF) hospitalization following hospitalization or need …